|Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023|
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA® (omadacycline) will be presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
The hybrid conference will be held April 15-18 at the Bella Center Copenhagen in Copenhagen, Denmark. View ECCMID scientific program here.
"We continue to generate new data to enhance understanding of NUZYRA's utility, both to enhance clinicians' confidence in prescribing it for patients with life-threatening, community-acquired infections as well as to explore its potential to address additional unmet needs," said Randy Brenner, chief development and regulatory officer of Paratek. "Accordingly, poster presentations at ECCMID feature a wide range of new research exploring effects of NUZYRA, including on microbiome diversity, against multi-drug resistant pathogens, in vitro activity against infrequently encountered bacterial pathogens, and the durability and safety of NUZYRA in nontuberculous mycobacteria (NTM) from a retrospective analysis."
NUZYRA presentation details:
Presentation Title: Gut microbiome diversity and bacterial taxonomic group changes in healthy volunteers receiving oral omadacycline or vancomycin*
Presentation Title: In vitro activity of omadacycline and comparator agents against 485 infrequently encountered bacterial pathogens from the SENTRY surveillance programme
Presentation Title: A multi-centre evaluation of treatment durability and safety of omadacycline for Mycobacterium abscessus infections*
Other Investigator-Initiated Research Supported by Paratek:
Presentation Title: Quantifying antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacteria infections: an opportunity for novel agents?*
Paratek is also contributing expertise and NUZYRA data to assist in the creation of a new, freely accessible platform for antimicrobial susceptibility data sharing funded by Wellcome Trust: Presentation details:
Presentation Title: AMR register: creation of a new, freely accessible platform for antimicrobial susceptibility data sharing
About Paratek Pharmaceuticals, Inc.
The company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, non-tuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.
In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA), now valued at up to $304 million, to support the development of omadacycline for pulmonary anthrax and the U.S.-based commercial manufacturing of NUZYRA.
For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.
Forward Looking Statements
|4/10/2023 7:30:00 AM